Merrill Lynch UK Inv Tst PLC
16 October 2002
MONTHLY PERFORMANCE
MERRILL LYNCH UK INVESTMENT TRUST plc
All information is at 30 September 2002 and unaudited.
Performance at month end with net income reinvested
One Three One Three Five
month months year years years
Net asset value -12.3% -21.8% -26.1% -45.6% -35.7%
Share price -19.2% -30.5% -34.5% -55.5% -50.1%
FTSE All-Share Index -11.8% -19.6% -20.8% -31.2% -16.8%
Sources: Merrill Lynch Investment Managers, Standard & Poor's Micropal
At month end
Net asset value* 602.99p
Share price: 455.00p
Discount: 24.5%
Total assets: £118.6m
Net Yield: 6.3%
Gearing: 49.9%
Effective gearing: 14.6%
Value of debt: £39.5m
Ordinary shares in issue: 13,368,799
*Includes current year net revenue of 11.40p.
UK Sectors % Total Assets
Financials 22.1
Cyclical Services 14.8
Non-Cyclical Consumer Goods 14.1
Resources 11.1
Non-Cyclical Services 7.2
Basic Industries 2.1
Utilities 2.0
General Industrials 1.7
Information Technology 1.2
Cash 25.5
Net current liabilities (1.8)
Total 100.0
Ten Largest Equity Investments
Company
% Investments
BP 8.8
GlaxoSmithKline 5.8
HSBC 5.8
HBOS 5.7
Barclays 5.2
Royal Bank of Scotland 4.4
Vodafone 4.1
AstraZeneca 3.8
Next 3.7
Amersham 3.6
Total 50.9
Market commentary
UK Stockmarket Review
The UK equity market was weak in September, with the FTSE All-Share falling
11.8%. Falls were particularly savage towards the end of the month, and the
FTSE 100 experienced its worst quarterly performance since the last three months
of 1987. September saw a continuation of August trends, with nervousness
surrounding economic growth prospects and shaky investor and consumer
confidence. These concerns were compounded by the prospect of a war in Iraq.
Performance Review
The Company's Net Asset Value (NAV) fell 12.3% in September, slightly behind the
FTSE All Share Index.
Defensive shares continued to outperform as falling stockmarkets caused
investors to seek the relative safety of companies with reliable and visible
earnings. Holdings in the healthcare sector, notably Amersham and Smith & Nephew
were helpful, although the lack of exposure to other defensive areas such as
food producers and electricity detracted from performance.
Banks remained under pressure and although we benefited from not holding Abbey
National, this was offset by the holdings in HBOS and Barclays, which also
underperformed. Life assurance companies continued to underperform, making the
sector one of the worst performers over the third quarter. Our low exposure here
was positive. Construction shares suffered on concerns over the future shape of
Public Finance Initiatives (PFI), and the Trust suffered from the holding in
McAlpine.
The overweight position in clothing retailer Next was particularly positive over
the month, as the shares continue to perform well. We benefited from our lack of
exposure to BAe Systems, which fell sharply after announcing a loss in the first
half of the year due to programme delays.
Outlook
Ongoing economic uncertainty and the potential for further corporate scandals
(both phenomena generally outside of the UK itself) are likely to perpetuate the
volatility and nervousness of the UK stockmarket. Over the longer term, there
are a number of trends within the UK that we expect to enhance earnings growth
for the companies involved. These include outsourcing, pricing power, volume
growth and corporate restructuring.
Latest information is available by typing www.mlim.co.uk/its on the internet,
'MLIMINDEX' on Reuters, 'MLIM' on Bloomberg or '8800' on Topic 3 (ICV terminal).
15 October 2002
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.